Join Milestone Pharmaceuticals for Part I of its virtual KOL event series for investors featuring George Mark, MD, FACC and Vivek Sailam, MD from The Heart House and Cooper University Health Care, who will discuss the burden of PSVT on patients and their practice, current treatments and unmet needs, and expectations for how the treatment landscape will evolve in coming years.

A live question and answer session will follow the formal presentation.

Etripamil is an investigational new drug, which is not approved for commercial distribution in the United States